All In Biotech

Drug Trial Radar · NCT04130516

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Oct 21, 2019

Primary completion

Jun 30, 2026

Study completion Aug 15, 2026

Sponsor

Lead sponsor
Linnaeus Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combination with pembrolizumab. The study will include a dose escalation phase, a dose expansion phase, and phase 2A cohorts. Up to 200 patients will be accrued for this study. Up to 15 study sites in the United States will participate in the study.

Conditions

  • Solid Tumor, Adult

Interventions

  • LNS8801 -Small molecule, orally bioavailable, selective agonist of GPERDrug

    LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER

  • Pembrolizumab - anti-PD-1 antibodyBiological

    pembrolizumab- anti-PD-1 antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events observed for LNS8801 dosed alone and in combination with pembrolizumabTime frame: Duration of study, approximately 24 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Yale Cancer Center

    New Haven, Connecticut

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of New Mexico Comprehensive Cancer Center

    Albuquerque, New Mexico

  • Columbia University Herbert Irving Comprehensive Cancer Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Thomas Jefferson University, Sidney Kimmel Cancer Center

    Philadelphia, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

  • The START Center for Cancer Care

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.